Observational
Yes
Answers are grounded in this paper and cite their sources.
Forecasts indicate a shifting global burden of cardiovascular-kidney-metabolic diseases by 2050, with declining CVD DALYs but rising DALYs for T2DM, CKD, and MASLD, emphasizing the need for better metabolic risk factor management.
Background Cardiovascular-kidney-metabolic health encompasses the complex interactions between metabolic risk factors, chronic kidney disease, and the cardiovascular system, significantly influencing both morbidity and mortality. Poor Cardiovascular-kidney-metabolic health can lead to widespread multisystem effects, with the most notable clinical consequence being the elevated risk of cardiovascular events and related mortality. Purpose This study aims to forecast the mortality and disability-adjusted life years (DALYs) associated with cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), from 2025 to 2050, stratified by Global Burden of Disease (GBD) super-regions, sex, sociodemographic index (SDI), and age-groups. Methods Historical and forecast data from 1990-2050 were obtained from the GBD 2021 study to examine mortality and DALYs associated with CVD, CKD, T2DM and MASLD, stratified by region, sex, SDI, and age. Results By 2050, age-standardised DALY rates per 100,000 population are projected to be the highest for CVDs (3,215 [2,412 to 4,305]), followed by T2DM (1,090 [842 to 1,382]), CKD (544 [393 to 750]), and MASLD (43 [31 to 57]). However, only CVDs saw a decline in age-standardised DALY rates from 2025 to 2050 (-31%). The other metabolic diseases, T2DM (22%), CKD (24%), and MASLD (1.5%) all saw a rise in age-standardised DALY rates. By 2050, males will continue to bear the brunt of the metabolic burden, It is projected that age-standardised DALY rates per 100,000 population will continue to be higher in males than females for CVD (52% higher), T2DM (18% higher), CKD (27% higher), and MASLD (16%). Regions with advanced health systems saw the greatest drop in age-standardised DALY rates due to CVD from 1990-2021, however, they also experienced the greatest rise in CKD, MASLD, and T2DM. In 2021, highest atherosclerotic CVD-related, CKD-related, MASLD-related and T2DM-related age standardised DALY rates were found in low to low-middle income countries, reflective of the trends of kidney-liver-metabolic risk factors, where regions with lower SDI bore the brunt of the burden. From 1990-2021, age-standardised DALY rates of risk factors associated with CVDs decreased, but rose for CKD, MASLD, and T2DM - particularly from high body mass index and high fasting plasma glucose. These trends are expected to persist into 2050. Conclusion While improvement in medical treatments have resulted in a reduction of CVD rates, the rise in CKD, T2DM, and MASLD reflects inadequate primary and secondary prevention, and environments that promote the development of cardiometabolic risk factors.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2025) conducted an observational in Cardiovascular-kidney-liver-metabolic diseases. Cardiometabolic risk factors and diseases was evaluated on Mortality and disability-adjusted life years (DALYs).
Synapse has enriched 10 related papers. Consider them for comparative context: